Screener
Bicara Therapeutics BCAX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders' equity: | ||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 500,000,000 and 500,000,000 shares authorized; 65,547,037 and 56,600,724 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 8 | 7 |
| Additional paid-in capital | 929,370 | 760,168 |
| Accumulated other comprehensive (loss) income | (243) | 243 |
| Accumulated deficit | (415,177) | (358,966) |
| Total stockholders' equity | 513,958 | 401,452 |
| Total liabilities and stockholders’ equity | $553,599 | $430,994 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's total equity?
- Bicara Therapeutics (BCAX) reported total equity of $513.96M in Q1 2026.
- How has Bicara Therapeutics's total equity changed year-over-year?
- Bicara Therapeutics's total equity increased by 12.0% year-over-year, from $458.96M to $513.96M.
- What is the long-term trend for Bicara Therapeutics's total equity?
- Over 3 years (2022 to 2025), Bicara Therapeutics's total equity has grown at a 59.6% compound annual growth rate (CAGR), from -$98.8M to $401.45M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Bicara Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude